Table 3. Clinicopathologic characteristics of the gastrointestinal cancer and adenocarcinoma of unknown primary with METex14del.
| Patient Number | Gender | Age | Site of tumor | Clinical findings | MET IHC | Nanostring | MET amplification (CEP7/MET) | Genetic alterations | MET variants detected in deep sequencing |
|---|---|---|---|---|---|---|---|---|---|
| PS-14-482 | F | 61 | Descending colon | Colon cancer with peritoneal seeding | 2+ | 173.42 | No (1:1) | KRAS-wild BRAF V600E mutation Microsatellite-stable |
c.3082+811TTTTAACA > GGTTTGAT (0.189) c.3082+115ATTTACCTC > TTGTTTGTT (0.095) c.3082+980CTATT > GATAA (0.121) c.3083–730del1 (0.058) c.3083–719TT > GA (0.056) c.3083–257AAGCA > GATCT (0.053) |
| PS-14-491 | M | 42 | Sigmoid colon | Colon cancer with multiple lymph node metastasis | 3+ | 174.29 | No (1:1.2) | KRAS-wild BRAF-wild TP53 and CTNNB1 mutation Microsatellite-unstable |
c.3082+811TTTTAACA > GGTTTGAT (0.140) c.2941+24T > C (0.262) c.3082+388TTGA > AATT (0.055) c.3082+716T > C (0.382) c.3083–1164TTTT > AGAC (0.057) c.3083–730del1 (0.061) c.3083–718TCTCC > CAGTT (0.071) |
| PS-14-536 | M | 87 | Descending colon | Colon cancer with obstruction, seeding | 3+ | 51.61 | No (1:0.9) | KRAS-wild BRAF-wild TP53 and APC mutation |
C.3082+811TTTTAACA > GGTTTGAT (0.062) c.3082+96A > G (0.061) c.3082+99A > C (0.061) c.3082+1430C > T (0.094) c.3083–731TAAAAAAAAAAAT > TAAAAAAAAAAAAT (0.083) c.3083–730 del1 (0.073) |
| PS-14-549 | F | 62 | Rectosigmoid colon | Colon cancer with distant metastasis | 3+ | 165.18 | No (1:1.1) | KRAS-wild BRAF V600E mutation Microsatellite-stable |
c.3082+811TTTTAACA > GGTTTGAT(0.272) c.3082+63GT > TC (0.093) c.3082+69TATT > TAAGC (0.089) c.3082+74T > C (0.098) c.3082+376GAAGC > AGCCG (0.232) c.3082+730TGAGTCA > CAACATGA(0.109) c.3082+1061T > G (0.278) c.3082+1082GAAAAAAAAAC > GAAAAAAAAAAC (0.050) c.3083–1342AG > GT (0.062) c.3083–1101GGCC > TTAT (0.231) c.3083–1070CC > GT (0.159) c.3083–1063A > G (0.062) c.3083–731TAAAAAAAAAAAT > TAAAAAAAAAAT (0.081) c.3083–523TACC > AATT (0.051) c.3083–330CAATTG > GAAAAA (0.054) c.3083–324CT > TA (0.052) c.3083–208GGGTAAAA > ACAGGAAG (0.054) |
| PS-14-260 | M | 52 | ACUP | Multiple lymph node enlargement without primary | 3+ | 193.64 | No (1:1.4) | KRAS-wild BRAF-wild TP53 and STK11 mutation Microsatellite-stable |
N(Continued )ot tested |
| PS-14-503 | M | 67 | Gastric | Gastric cancer with ascites | 3+ | □ 121 | Yes (1:12.8) | TP53 p.V73M mutation | c.3082+811TTTTAACA > GGTTTGAT (0.134) c.3082+1082GAAAAAAAAAC > GAAAAAAAAAAC (0.055) c.3083–731TAAAAAAAAAAAT > TAAAAAAAAAAT (0.089) |
| PS-14-658 | M | 27 | Gastric | Gastric cancer with multiple lymphadenopathy and ascites | 3+ | □ 131 | No (1:0.75) | TP53 p.R141H mutation CDH1 p.G352fs mutation Polysomy-7 |
c.3082+811TTTTAACA > GGTTTGAT (0.070) c.3083–731TAAAAAAAAAAAT > TAAAAAAAAAAT (0.117) c.3083–730del1 (0.088) |
| PS-14-875 | F | 64 | Gastric | Gastric cancer with seeding | 3+ | □ 142 | No (1:1) | PTEN P.V119D mutation | c.3082+811TTTTAACA > GGTTTGAT (0.113) c.3082+730TGAG > CAACA (0.056) c.3082+735C > G (0.057) c.3082+1281GCAGAGCTT > TAAAAGGAG (0.062) c.3083–1320A > C (0.082) c.3083–1317G > T (0.082) c.3083–1041GT > CA (0.055) c.3083–860GTCAGTTGC > AACACTCAG (0.068) c.3083 731TAAAAAAAAAAAT > TAAAAAAAAAAT (0.113) c.3083–730del1 (0.075) c.3083–208GGGTAAAA > ACAGGAAG (0.087) |